FDA approves nasal spray to treat rapid heart rhythm

In late 2025, the FDA approved a nasal spray to treat a sporadic, rapid heart rhythm called paroxysmal supraventricular tachycardia (PSVT). The self-administered spray, called etripamil (Cardamyst), may help people avoid emergency room treatment for PSVT.